Skip to main content
Clinical Trials/PACTR202004888024754
PACTR202004888024754
Completed
未知

Serial correlation of temporal pain intensities with beta-endorphin and meta-enkephalin concentrations, following Transcutaneous Electrical Nerve Stimulation among patients with chronic low back pain: a randomized controlled trial

Charles Ikechukwu Ezema0 sites70 target enrollmentMarch 15, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Charles Ikechukwu Ezema
Enrollment
70
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The results showed that the reported PI values were significantly lower for TENS patient than sham-TENS patients at immediate post-treatment (M.D = -3, t = -6.616, p = 0.000) and 1 hr times (M.D = -3, t = -6.893, p = 0.000). However, there were no significant differences at 24 hrs or 48 hrs (or at baseline). The correlation between PI, ßE and ME was not significant. It was concluded that TENS application significantly reduces PI but does not cause any significant change in plasma concentration of ßE and ME in patients with CLBP.

Registry
who.int
Start Date
March 15, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Charles Ikechukwu Ezema

Eligibility Criteria

Inclusion Criteria

  • ambulatory male or female patients aged 20–70 years
  • who had been clinically diagnosed of CLBP resulting from lumbar spondylosis of not less than six months duration
  • with pain intensity NRS \= 5
  • who were referred for physiotherapy,

Exclusion Criteria

  • previous use of therapeutic electrical stimulation modality
  • prior lumbar spine surgery
  • history of cancer, cardiovascular, gynaecological, urological, and neurologic conditions
  • severe spinal orthopaedic conditions such as pott’s disease, disc protrusion, lumbar (spinal and foramina) stenosis, radiculopathy, and spondylolisthesis \> 1 cm
  • skin lesions between L1 to L5
  • pain on vertical oscillatory thrust of any spinal vertebrae beyond L1 to L5
  • pain from hips and sacroiliac joints
  • implanted electronic device (pacemaker)
  • use of steroids and central nervous system stimulants

Outcomes

Primary Outcomes

Not specified

Similar Trials